Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.60 |
| ▸ | GAA | P10253 | 9/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MC4R | P32245 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.59 |
| ▸ | CLK1 | P49759 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 1/20 | 0.59 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23575854 | 0.93 | MAPT (0.59) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23575650 | 0.88 | CSF1R (0.57) | — | |
| SCHEMBL23575597 | 0.88 | MAPT (0.59) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23575806 | 0.85 | GAA (0.51) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL23575359 | 0.85 | MAPT (0.65) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL29220526 | 0.85 | POLB (0.51) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL23575564 | 0.81 | CSF1R (0.54) | SLC2A1 | |
| SCHEMBL29220515 | 0.81 | POLB (0.49) | MAPTSMN1; SMN2MEN1KMT2ALMNA | |
| SCHEMBL20897318 | 0.79 | MAPT (0.58) | MAPTGAASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16719270 | 0.79 | MTOR (0.53) | MAPTGAASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3846800-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 Therapeutics, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | C4 THERAPEUTICS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198256-A1 | COMPOUNDS FOR THE DEGRADATION OF BRD9 OR MTH1 | RBBP9, MTHFD1, BRWD1 | MAPT 843/4885GAA 1619/4885SMN1; SMN2 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.